Wall Street Zen Upgrades BioMarin Pharmaceutical (NASDAQ:BMRN) to Buy

BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

Other analysts also recently issued research reports about the company. Citigroup lifted their price target on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Sanford C. Bernstein reduced their price objective on BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th. HC Wainwright increased their price objective on BioMarin Pharmaceutical from $50.00 to $60.00 and gave the stock a “neutral” rating in a report on Friday. Royal Bank Of Canada dropped their target price on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating on the stock in a research report on Tuesday, July 7th. Finally, Morgan Stanley boosted their target price on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an “overweight” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $87.86.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock opened at $63.81 on Friday. The stock has a market capitalization of $12.35 billion, a PE ratio of 172.46, a price-to-earnings-growth ratio of 0.49 and a beta of 0.24. BioMarin Pharmaceutical has a twelve month low of $49.26 and a twelve month high of $66.28. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. The company has a 50 day moving average of $58.19 and a 200-day moving average of $57.08.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The company had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. During the same quarter in the prior year, the firm earned $1.44 earnings per share. The firm’s revenue was up 20.0% compared to the same quarter last year. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, equities research analysts anticipate that BioMarin Pharmaceutical will post 4.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Citizens Financial Group Inc. RI acquired a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth approximately $245,000. Grandfield & Dodd LLC acquired a new stake in BioMarin Pharmaceutical in the second quarter valued at $1,044,000. Pallas Capital Advisors LLC bought a new position in shares of BioMarin Pharmaceutical in the 2nd quarter valued at about $397,000. Deutsche Bank AG bought a new position in shares of BioMarin Pharmaceutical in the 2nd quarter valued at about $7,226,000. Finally, Rice Hall James & Associates LLC acquired a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth about $14,203,000. 98.71% of the stock is currently owned by institutional investors.

Trending Headlines about BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q2 results exceeded expectations. BioMarin reported adjusted earnings of $1.20 per share versus the $0.95–$0.96 analyst consensus, while revenue rose 20% year over year to approximately $990 million, ahead of estimates near $932 million. BioMarin Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 outlook. Full-year adjusted EPS guidance increased to $4.90-$5.10 from a prior level below that range and above the roughly $4.80 consensus. Revenue guidance was set around $3.9 billion. Stronger-than-expected VOXZOGO sales and continued momentum in key therapies supported the revision. BioMarin Reports Second Quarter 2026 Results
• Positive Sentiment: Amicus additions could improve long-term growth. BioMarin said the addition of GALAFOLD and POMBILITI plus OPFOLDA, along with cost synergies, should accelerate revenue growth, earnings accretion, operating-margin expansion and cash flow through the mid-2030s. BioMarin Lifts 2026 Outlook
• Positive Sentiment: Morgan Stanley raised its price target to $124 from $119 and maintained an Overweight rating, signaling substantial potential upside in its valuation view.
• Neutral Sentiment: HC Wainwright increased its target to $60 from $50 but retained a Neutral rating, indicating more cautious expectations than Morgan Stanley.
• Negative Sentiment: BioMarin discontinued a $270 million rare-disease asset after the treatment missed its Phase 3 endpoint. The setback removes a potential growth opportunity and highlights clinical-development risk. BioMarin Axes Rare-Disease Asset

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.